|
| Status |
Public on Nov 30, 2016 |
| Title |
GEN2.2-0 hrs post CpGB-MYC siRNA-rep 3 |
| Sample type |
RNA |
| |
|
| Source name |
GEN2.2-0 hrs post CpGB-MYC siRNA
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: GEN2.2
hrs post cpgb stimulation: 0
sirna: MYC
replicate: 3
|
| Treatment protocol |
GEN2.2 cells were myc-ablated by Nucleofection (Nucleofector kit V, www.lonza.com). GEN2.2 cells were nucleofected with nucleofector kit V (Amaxa) with 0.4 nmol of siRNA for each reaction of 3-5 × 10^6 cells. siMYC and siHDAC3 were purchased from Dharmacon. The program number for electroporation was A033. The non-targeting control (NC) is a non-targeting pool from Dharmacon. GEN2.2 cells were stimulated with 0.5 µM of CpGB
|
| Growth protocol |
GEN2.2 cells were kindly provided by Dr. Joël Plumas (Université Joseph Fourier, Grenoble, France) and cultured in GlutaMax-RPMI (GIBCO) supplemented with 10% FBS (Atlanta), MEM-nonessential amino acid solution (GIBCO), sodium pyruvate and gentamycin.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA isolation was performed using Qiagen RNeasy mini kit according to the manufacturer’s instructions
|
| Label |
biotin
|
| Label protocol |
Standard Illumina labelling protocol.
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol.
|
| Scan protocol |
Standard Illumina scanning protocol.
|
| Description |
9373549130_J
|
| Data processing |
Standard Average Normalization as detailed by GenomeStudio
|
| |
|
| Submission date |
Jun 25, 2015 |
| Last update date |
Mar 16, 2023 |
| Contact name |
Nicole Baldwin |
| E-mail(s) |
Nicole.Baldwin@BSWHealth.org
|
| Organization name |
Baylor Research Institute
|
| Street address |
3434 Live Oak St
|
| City |
Dallas |
| ZIP/Postal code |
75204 |
| Country |
USA |
| |
|
| Platform ID |
GPL10558 |
| Series (2) |
| GSE70276 |
Transcriptional repression of IRF7 by MYC is critical for antiviral immune response in human pDC [GEN2.2] |
| GSE70278 |
Transcriptional repression of IRF7 by MYC is critical for antiviral immune response in human pDC |
|
